Daito Pharmaceutical (4577) Fundamentals 2026 — P/E 11.8x, Revenue Analysis | SniperIQ
Daito Pharmaceutical (4577) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥36.5B, trading at ¥1271.00 on the JPX. This SniperIQ fundamentals page covers Daito Pharmaceutical's valuation (P/E 11.8x, P/B 0.7x), profitability (net margin 6.2%), revenue (¥50.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daito Pharmaceutical's market cap?
Daito Pharmaceutical (4577) has a market capitalization of approximately ¥36.5B, trading at ¥1271.00 on the JPX. Market cap moves with the live share price.
What is Daito Pharmaceutical's P/E ratio?
Daito Pharmaceutical's trailing twelve-month P/E ratio is 11.8x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daito Pharmaceutical?
Daito Pharmaceutical runs a net profit margin of 6.2%, a gross margin of 19.5%, and an operating margin of 7.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daito Pharmaceutical generate?
Daito Pharmaceutical reported revenue of ¥50.6B for fiscal year 2025, with net income of ¥3.2B and earnings per share (EPS) of 107.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daito Pharmaceutical pay a dividend?
Daito Pharmaceutical offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Daito Pharmaceutical financially healthy?
Daito Pharmaceutical carries a debt-to-equity ratio of 0.18x and a current ratio of 2.62x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daito Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daito Pharmaceutical (4577) the key facts are: market cap ¥36.5B, P/E 11.8x, revenue ¥50.6B, 52-week range 1120-1521. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daito Pharmaceutical's full fundamentals live
Get Daito Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.